Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kura Preclinical Data Supports Ziftomenib for Gastrointestinal Tumors
Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated in combination with imatinib for the treatment of patients with advanced gastrointestinal stromal tumors.
Brand Name : KO-539
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2024
Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kura Oncology Receives FDA IND Clearance For Menin Inhibitor Ziftomenib in GIST
Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated in combination with imatinib for the treatment of patients with advanced gastrointestinal stromal tumors.
Brand Name : KO-539
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 08, 2024
Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kura Oncology Completes Enrollment in Reg-Directed Trial of Ziftomenib in NPM1-Mutant AML
Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated for the treatment of patients with relapsed/refractory NPM1-mutant acute myeloid leukemia (AML).
Brand Name : KO-539
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 14, 2024
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Details : KO-539 (ziftomenib) is a menin-KMT2A/MLL inhibitor that has received Breakthrough Therapy Designation from the FDA for treating relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML).
Brand Name : KO-539
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 22, 2024
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ziftomenib,Gilteritinib Fumarate,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : AstraZeneca
Deal Size : Not Applicable
Deal Type : Not Applicable
Kura Doses First Patient in KOMET-008 Trial of Ziftomenib with Standards of Care in AML
Details : KO-539 (ziftomenib) is a potent and selective a menin-MLL(KMT2A) inhibitor, which is being evaluated in phase 1 clinical trials in patients with NPM1-mutant & KMT2A-rearranged acute myeloid leukemia.
Brand Name : KO-539
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 26, 2024
Lead Product(s) : Ziftomenib,Gilteritinib Fumarate,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : AstraZeneca
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kura Reports Positive Preliminary Ziftomenib Combination Data in AML
Details : KO-539 (ziftomenib) is a potent and selective a menin-MLL(KMT2A) inhibitor, which is being evaluated in phase 2 clinical trials in patients with NPM1-mutant & KMT2A-rearranged acute myeloid leukemia.
Brand Name : KO-539
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 30, 2024
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : EcoR1 Capital
Deal Size : $150.0 million
Deal Type : Private Placement
Kura Oncology Announces Oversubscribed $150 Million Private Placement
Details : Kura will use proceeds for R&D of its clinical-stage candidates, including KO-539 (ziftomenib), an oral menin-KMT2A inhibitor for treating Acute Myeloid Leukemia.
Brand Name : KO-539
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 24, 2024
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : EcoR1 Capital
Deal Size : $150.0 million
Deal Type : Private Placement
Lead Product(s) : Ziftomenib,Fludarabine Phosphate,Idarubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Leukemia & Lymphoma Society
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to evaluate Kura’s menin inhibitor, KO-539 (ziftomenib), in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-rearranged or NPM1-mutant acute leukemia.
Brand Name : KO-539
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 08, 2023
Lead Product(s) : Ziftomenib,Fludarabine Phosphate,Idarubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Leukemia & Lymphoma Society
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : BofA Securities
Deal Size : $100.0 million
Deal Type : Public Offering
Details : The net proceeds will be used to advance company's pipeline of product candidates, including continued development of KO-539 (ziftomenib), a potent and selective small molecule inhibitor of the menin-MLL protein-protein interaction, tipifarnib and KO-280...
Brand Name : KO-539
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 14, 2023
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : BofA Securities
Deal Size : $100.0 million
Deal Type : Public Offering
Lead Product(s) : Ziftomenib,Gilteritinib Fumarate
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : BofA Securities
Deal Size : $100.0 million
Deal Type : Public Offering
Details : The net proceeds will be used for the development of KO-539 (ziftomenib), a potent and selective inhibitor, being developed in combination with Xospata (gilteritinib), an inhibitor of FLT3, for the treatment of NPM1-mutated acute myeloid leukemia.
Brand Name : KO-539
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 14, 2023
Lead Product(s) : Ziftomenib,Gilteritinib Fumarate
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : BofA Securities
Deal Size : $100.0 million
Deal Type : Public Offering
LOOKING FOR A SUPPLIER?